Royalty Pharma PLC $RPRX Shares Purchased by Tredje AP fonden

Tredje AP fonden grew its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 44.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 53,464 shares of the biopharmaceutical company’s stock after acquiring an additional 16,545 shares during the quarter. Tredje AP fonden’s holdings in Royalty Pharma were worth $2,066,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Strs Ohio increased its holdings in shares of Royalty Pharma by 2.8% during the fourth quarter. Strs Ohio now owns 9,318 shares of the biopharmaceutical company’s stock valued at $360,000 after acquiring an additional 252 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in shares of Royalty Pharma by 0.6% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 43,287 shares of the biopharmaceutical company’s stock valued at $1,673,000 after acquiring an additional 255 shares in the last quarter. Private Trust Co. NA increased its holdings in shares of Royalty Pharma by 52.9% during the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 288 shares in the last quarter. Hudson Bay Capital Management LP increased its holdings in shares of Royalty Pharma by 1.0% during the third quarter. Hudson Bay Capital Management LP now owns 29,384 shares of the biopharmaceutical company’s stock valued at $1,037,000 after acquiring an additional 289 shares in the last quarter. Finally, Truist Financial Corp increased its holdings in shares of Royalty Pharma by 1.1% during the fourth quarter. Truist Financial Corp now owns 27,769 shares of the biopharmaceutical company’s stock valued at $1,073,000 after acquiring an additional 303 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on RPRX shares. Wall Street Zen upgraded shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Morgan Stanley increased their price target on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a report on Friday, April 10th. UBS Group increased their price target on shares of Royalty Pharma from $51.00 to $57.00 and gave the stock a “buy” rating in a report on Tuesday, April 21st. Citigroup increased their price target on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, Weiss Ratings downgraded shares of Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 15th. Seven investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $53.71.

Insider Transactions at Royalty Pharma

In other news, Director Gregory Norden sold 3,045 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $53.00, for a total transaction of $161,385.00. Following the sale, the director owned 191,803 shares of the company’s stock, valued at $10,165,559. This trade represents a 1.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 34,791 shares of the firm’s stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $49.78, for a total transaction of $1,731,895.98. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 155,893 shares of company stock valued at $7,512,360 in the last 90 days. 18.84% of the stock is currently owned by company insiders.

Royalty Pharma Price Performance

Shares of NASDAQ:RPRX opened at $53.06 on Thursday. Royalty Pharma PLC has a twelve month low of $32.15 and a twelve month high of $53.47. The company’s 50 day moving average is $48.72 and its 200 day moving average is $43.73. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. The company has a market cap of $30.55 billion, a PE ratio of 36.10, a price-to-earnings-growth ratio of 1.44 and a beta of 0.40.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The company had revenue of $631.00 million for the quarter, compared to the consensus estimate of $881.69 million. On average, sell-side analysts forecast that Royalty Pharma PLC will post 5.05 EPS for the current year.

Royalty Pharma Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a dividend of $0.235 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.8%. Royalty Pharma’s dividend payout ratio (DPR) is presently 63.95%.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.